Clomipramine Pathway, Pharmacokinetics

Pathway network for the Clomipramine Pathway, Pharmacokinetics SuperPath

Sources:

PharmGKB
PubChem
WikiPathways
Reactome

Pathways in the Clomipramine Pathway, Pharmacokinetics SuperPath

#	Name	Source	Genes
1	Clomipramine Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C19 CYP2D6 CYP3A4
2	Clozapine Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCC1 ABCG2 CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP2E1 CYP3A4 CYP3A43 CYP3A5 FMO3 SLC22A1 SLC22A2 SLC22A3 UGT1A1 UGT1A3 UGT1A4 UGT2B10 (see all 19) (see less)
3	Carbamazepine Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCC2 CYP1A2 CYP2A6 CYP2B6 CYP2C19 CYP2C8 CYP2E1 CYP3A4 CYP3A5 CYP3A7 EPHX1 MPO NR1I2 NR1I3 RALBP1 UGT2B7 (see all 17) (see less)
4	Amitriptyline and Nortriptyline Pathway, Pharmacokinetics	PharmGKB	ABCB1 AKR1C1 AKR1C2 CYP1A2 CYP2C19 CYP2C8 CYP2C9 CYP2D6 CYP3A4 FMO3 UGT1A3 UGT1A4 UGT2B10 (see all 13) (see less)
5	Momelotinib Pathway. Pharmacokinetics/Pharmacodynamics	PharmGKB	ABCB1 ABCG2 ACVR1 AOX1 CYP1A2 CYP2C19 CYP2C8 CYP2C9 CYP3A4 JAK1 JAK2 SLCO1B1 SLCO1B3 (see all 13) (see less)
6	Mitotane Pathway, Pharmacokinetics/Pharmacodynamics	PharmGKB	ABCB1 ABCG2 CYP1A1 CYP1A2 CYP2C19 CYP2D6 CYP2W1 CYP3A4 NR1I2 SLCO1B1 SOAT1 UGT1A3 (see all 12) (see less)
7	Vandetanib Pathway, Pharmacokinetics/Pharmacodynamics	PharmGKB	CYP1A1 CYP2C8 CYP2D6 CYP3A4 CYP3A5 EGFR FMO1 FMO3 KCNH2 KDR RET (see all 11) (see less)
8	Olanzapine Pathway, Pharmacokinetics	PharmGKB	ABCB1 CYP1A2 CYP2C8 CYP2D6 CYP3A4 CYP3A43 CYP3A5 FMO1 FMO3 UGT1A4 UGT2B10 (see all 11) (see less)
9	Estrogen Metabolism Pathway, Pharmacokinetics	PharmGKB	COMT CYP19A1 CYP1A1 CYP1A2 CYP1B1 CYP3A4 CYP3A5 HSD17B1 SULT1A1 (see all 9) (see less)
10	Warfarin Pathway, Pharmacokinetics	PharmGKB	ABCB1 CYP1A1 CYP1A2 CYP2C18 CYP2C19 CYP2C8 CYP2C9 CYP3A4 (see all 8) (see less)
11	Efavirenz Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2A6 CYP2B6 CYP3A4 CYP3A5 NR1I2 NR1I3 UGT2B7 (see all 8) (see less)
12	Vortioxetine Pathway, Pharmacokinetics	PharmGKB	AOX1 CYP2A6 CYP2C19 CYP2C8 CYP2C9 CYP2D6 CYP3A4 CYP3A5 (see all 8) (see less)
13	Melatonin Pathway, Pharmacokinetics	PharmGKB	ASMT CYP1A1 CYP1A2 CYP1B1 CYP2C19 CYP2C9 CYP2D6 (see all 7) (see less)
14	Verapamil Pathway, Pharmacokinetics	PharmGKB	ABCB1 CYP1A2 CYP2C8 CYP2D6 CYP2E1 CYP3A4 CYP3A5 (see all 7) (see less)
15	Paroxetine Pathway, Pharmacokinetics	PharmGKB	ABCB1 COMT CYP1A2 CYP2C19 CYP2D6 CYP3A4 CYP3A5 (see all 7) (see less)
16	Berberine Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C19 CYP2D6 CYP2E1 CYP3A4 SLC22A1 (see all 6) (see less)
17	Nevirapine Pathway, Pharmacokinetics	PharmGKB	ABCC10 CYP2B6 CYP2C9 CYP2D6 CYP3A4 CYP3A5 (see all 6) (see less)
18	Doxepin Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4
19	Bortezomib Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4
20	superpathway of melatonin degradation	PubChem	CYP1A2 CYP1B1 CYP2C19 MPO SULT1A2
21	melatonin degradation I	PubChem	CYP1A2 CYP1B1 CYP2C19 SULT1A2
22	Metoprolol Pathway, Pharmacokinetics	PharmGKB	CYP2B6 CYP2C9 CYP2D6 CYP3A4
23	Aprepitant Pathway, Pharmacokinetics/Pharmacodynamics	PharmGKB	CYP1A2 CYP2C19 CYP3A4 TACR1
24	Imipramine/Desipramine Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C19 CYP2D6 CYP3A4
25	Pantoprazole Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCG2 CYP2C19 CYP3A4
26	Gliclazide Pathway, Pharmacokinetics	PharmGKB	CYP2C18 CYP2C19 CYP2C8 CYP2C9
27	Acenocoumarol Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C18 CYP2C19 CYP2C9
28	Dextromethorphan Pathway, Pharmacokinetics	PharmGKB	CYP2B6 CYP2D6 CYP3A4
29	Abemaciclib Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCG2 CYP3A4
30	Rabeprazole Pathway, Pharmacokinetics	PharmGKB	CYP2C19 CYP2D6 CYP3A4
31	Pirfenidone Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2C19 CYP2D6
32	Avatrombopag Pathway, Pharmacokinetics	PharmGKB	ABCB1 CYP2C9 CYP3A4
33	Candesartan Pathway, Pharmacokinetics	PharmGKB	ABCB1 CYP2C9
34	Aripiprazole metabolic pathway	WikiPathways	CYP2D6 CYP3A43
35	Duloxetine Pathway, Pharmacokinetics	PharmGKB	CYP1A2 CYP2D6
36	Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2	Reactome	CYP1A2
37	bupropion degradation	PubChem	CYP2B6
38	Febuxostat Pathway, Pharmacokinetics	PharmGKB	ABCG2

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	26
2	CYP1A2	Cytochrome P450 Family 1 Subfamily A Member 2	Protein Coding	24
3	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	22
4	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6 (Gene/Pseudogene)	Protein Coding	21
5	CYP2C9	Cytochrome P450 Family 2 Subfamily C Member 9	Protein Coding	14
6	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	13
7	CYP3A5	Cytochrome P450 Family 3 Subfamily A Member 5	Protein Coding	10
8	CYP2C8	Cytochrome P450 Family 2 Subfamily C Member 8	Protein Coding	9
9	ABCG2	ATP Binding Cassette Subfamily G Member 2 (JR Blood Group)	Protein Coding	6
10	CYP2B6	Cytochrome P450 Family 2 Subfamily B Member 6	Protein Coding	6
11	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	5
12	FMO3	Flavin Containing Dimethylaniline Monoxygenase 3	Protein Coding	4
13	CYP2E1	Cytochrome P450 Family 2 Subfamily E Member 1	Protein Coding	4
14	CYP1B1	Cytochrome P450 Family 1 Subfamily B Member 1	Protein Coding	4
15	CYP3A43	Cytochrome P450 Family 3 Subfamily A Member 43	Protein Coding	3
16	UGT2B10	UDP Glucuronosyltransferase Family 2 Member B10	Protein Coding	3
17	UGT1A4	UDP Glucuronosyltransferase Family 1 Member A4	Protein Coding	3
18	UGT1A3	UDP Glucuronosyltransferase Family 1 Member A3	Protein Coding	3
19	NR1I2	Nuclear Receptor Subfamily 1 Group I Member 2	Protein Coding	3
20	CYP2A6	Cytochrome P450 Family 2 Subfamily A Member 6	Protein Coding	3
21	CYP2C18	Cytochrome P450 Family 2 Subfamily C Member 18	Protein Coding	3
22	SLC22A1	Solute Carrier Family 22 Member 1	Protein Coding	2
23	UGT2B7	UDP Glucuronosyltransferase Family 2 Member B7	Protein Coding	2
24	MPO	Myeloperoxidase	Protein Coding	2
25	NR1I3	Nuclear Receptor Subfamily 1 Group I Member 3	Protein Coding	2
26	AOX1	Aldehyde Oxidase 1	Protein Coding	2
27	SLCO1B1	Solute Carrier Organic Anion Transporter Family Member 1B1	Protein Coding	2
28	FMO1	Flavin Containing Dimethylaniline Monoxygenase 1	Protein Coding	2
29	COMT	Catechol-O-Methyltransferase	Protein Coding	2
30	SULT1A2	Sulfotransferase Family 1A Member 2	Protein Coding	2
31	SLC22A3	Solute Carrier Family 22 Member 3	Protein Coding	1
32	SLC22A2	Solute Carrier Family 22 Member 2	Protein Coding	1
33	UGT1A1	UDP Glucuronosyltransferase Family 1 Member A1	Protein Coding	1
34	ABCC1	ATP Binding Cassette Subfamily C Member 1 (ABCC1 Blood Group)	Protein Coding	1
35	RALBP1	RalA Binding Protein 1	Protein Coding	1
36	EPHX1	Epoxide Hydrolase 1	Protein Coding	1
37	CYP3A7	Cytochrome P450 Family 3 Subfamily A Member 7	Protein Coding	1
38	ABCC2	ATP Binding Cassette Subfamily C Member 2	Protein Coding	1
39	AKR1C1	Aldo-Keto Reductase Family 1 Member C1	Protein Coding	1
40	AKR1C2	Aldo-Keto Reductase Family 1 Member C2	Protein Coding	1
41	JAK1	Janus Kinase 1	Protein Coding	1
42	JAK2	Janus Kinase 2	Protein Coding	1
43	SLCO1B3	Solute Carrier Organic Anion Transporter Family Member 1B3	Protein Coding	1
44	ACVR1	Activin A Receptor Type 1	Protein Coding	1
45	SOAT1	Sterol O-Acyltransferase 1	Protein Coding	1
46	CYP2W1	Cytochrome P450 Family 2 Subfamily W Member 1	Protein Coding	1
47	RET	Ret Proto-Oncogene	Protein Coding	1
48	KCNH2	Potassium Voltage-Gated Channel Subfamily H Member 2	Protein Coding	1
49	KDR	Kinase Insert Domain Receptor	Protein Coding	1
50	EGFR	Epidermal Growth Factor Receptor	Protein Coding	1
51	SULT1A1	Sulfotransferase Family 1A Member 1	Protein Coding	1
52	HSD17B1	Hydroxysteroid 17-Beta Dehydrogenase 1	Protein Coding	1
53	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	1
54	ASMT	Acetylserotonin O-Methyltransferase	Protein Coding	1
55	ABCC10	ATP Binding Cassette Subfamily C Member 10	Protein Coding	1
56	TACR1	Tachykinin Receptor 1	Protein Coding	1

Disorders associated with Clomipramine Pathway, Pharmacokinetics SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Crigler-najjar syndrome, type i	Enrichment	UGT1A1, UGT1A3, UGT1A4	6.56
2	Hyperbilirubinemia, transient familial neonatal	Enrichment	UGT1A1, UGT1A3, UGT1A4	6.56
3	Bilirubin, serum level of, quantitative trait locus 1	Enrichment	UGT1A1, UGT1A3, UGT1A4	6.56
4	Crigler-najjar syndrome, type ii	Enrichment	UGT1A1, UGT1A3, UGT1A4	6.56
5	Gilbert syndrome	Enrichment	UGT1A1, UGT1A3, UGT1A4	6.42
6	Bilirubin metabolic disorder	Enrichment	UGT1A1, UGT1A3, UGT1A4	6.42
7	Coumarin resistance	Enrichment	CYP2A6, CYP2C9	6.04
8	Hyperbilirubinemia, rotor type	Enrichment	SLCO1B1, SLCO1B3	5.59
9	Breast implant-associated anaplastic large cell lymphoma	Enrichment	JAK1, JAK2	5.59
10	Efavirenz, poor metabolism of	Enrichment	CYP2B6	4.13
11	Uric acid concentration, serum, quantitative trait locus 1	Enrichment	ABCG2	4.13
12	Blood group, junior system	Enrichment	ABCG2	4.13
13	Colchicine resistance	Enrichment	ABCB1	3.83
14	Encephalopathy, acute transient	Enrichment	ABCB1	3.83
15	Inflammatory bowel disease 13	Enrichment	ABCB1	3.83
16	Drug metabolism, poor, cyp2d6-related	Enrichment	CYP2D6	3.83
17	Tetralogy of fallot	Enrichment	KDR, RET	3.72
18	Vitamin d-dependent rickets, type 3	Enrichment	CYP3A4	3.66
19	Drug metabolism, poor, cyp2c19-related	Enrichment	CYP2C19	3.66
20	Drug metabolism, altered, cyp2c8-related	Enrichment	CYP2C8	3.53
21	Catechol-o-methyltransferase activity, variation in	Enrichment	COMT	3.29
22	Glaucoma 1, open angle, a	Enrichment	CYP1B1	3.23
23	Anterior segment dysgenesis 6	Enrichment	CYP1B1	3.23
24	Primary congenital glaucoma	Enrichment	CYP1B1	3.23
25	Letrozole toxicity	Enrichment	CYP2A6	3.23
26	Multiple endocrine neoplasia, type iib	Enrichment	RET	3.09
27	Short qt syndrome 1	Enrichment	KCNH2	3.09
28	Tufted angioma of skin	Enrichment	KDR	3.09
29	Thyroid cancer	Enrichment	RET	3.09
30	Severe primary trimethylaminuria	Enrichment	FMO3	3.09
31	Gastrointestinal system disease	Enrichment	RET	3.09
32	Multiple endocrine neoplasia	Enrichment	RET	3.09
33	Mendelian susceptibility to mycobacterial diseases due to partial jak1 deficiency	Enrichment	JAK1	3.02
34	Glaucoma 3, primary infantile, b	Enrichment	CYP1B1	2.93
35	Genetic lipodystrophy	Enrichment	EPHX1	2.90
36	Deafness, autosomal dominant 77	Enrichment	ABCC1	2.85
37	Myeloperoxidase deficiency	Enrichment	MPO	2.83
38	Juvenile glaucoma	Enrichment	CYP1B1	2.83
39	Angioma, tufted	Enrichment	KDR	2.79
40	Trimethylaminuria	Enrichment	FMO3	2.79
41	Medullary thyroid carcinoma	Enrichment	RET	2.79
42	Primary trimethylaminuria	Enrichment	FMO3	2.79
43	Epilepsy, idiopathic generalized	Enrichment	ABCB1	2.79
44	Glaucoma, primary open angle	Enrichment	CYP1B1	2.75
45	Anterior segment dysgenesis 5	Enrichment	CYP1B1	2.75
46	Cic-rearranged sarcoma	Enrichment	AKR1C2	2.72
47	Fibrodysplasia ossificans progressiva	Enrichment	ACVR1	2.72
48	Thrombocythemia 3	Enrichment	JAK2	2.72
49	Autoinflammation, immune dysregulation, and eosinophilia	Enrichment	JAK1	2.72
50	Polycythemia	Enrichment	JAK2	2.72
51	Hypereosinophilic syndrome	Enrichment	JAK2	2.72
52	Aromatase excess syndrome	Enrichment	CYP19A1	2.70
53	Aromatase deficiency	Enrichment	CYP19A1	2.70
54	Glaucoma 3, primary congenital, a	Enrichment	CYP1B1	2.69
55	Tobacco addiction	Enrichment	CYP2A6	2.63
56	Thyroid carcinoma, familial medullary	Enrichment	RET	2.61
57	Neonatal nephrocutaneous inflammatory syndrome	Enrichment	EGFR	2.61
58	Immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation	Enrichment	KCNH2	2.61
59	Gingival overgrowth	Enrichment	RET	2.61
60	Neonatal inflammatory skin and bowel disease	Enrichment	EGFR	2.61
61	Alzheimer's disease 1	Enrichment	MPO	2.59
62	46,xy sex reversal 8	Enrichment	AKR1C2	2.54
63	Polycythemia vera	Enrichment	JAK2	2.54
64	Ovarian cancer	Enrichment	EGFR, RET	2.54
65	Peters-plus syndrome	Enrichment	CYP1B1	2.53
66	Long qt syndrome 2	Enrichment	KCNH2	2.49
67	Cardiomyopathy, familial hypertrophic, 26	Enrichment	KCNH2	2.49
68	Central hypoventilation syndrome, congenital, 1	Enrichment	RET	2.49
69	Haddad syndrome	Enrichment	RET	2.49
70	Dubin-johnson syndrome	Enrichment	ABCC2	2.43
71	Erythrocytosis, familial, 1	Enrichment	JAK2	2.42
72	Budd-chiari syndrome	Enrichment	JAK2	2.42
73	Multiple endocrine neoplasia, type iia	Enrichment	RET	2.39
74	Congenital short qt syndrome	Enrichment	KCNH2	2.39
75	Anterior segment dysgenesis	Enrichment	CYP1B1	2.35
76	Myeloproliferative neoplasm	Enrichment	JAK2	2.32
77	Alzheimer's disease	Enrichment	MPO	2.32
78	Cowden syndrome 1	Enrichment	EGFR	2.31
79	Hemangioma, capillary infantile	Enrichment	KDR	2.31
80	Lung squamous cell carcinoma	Enrichment	EGFR	2.31
81	Sporadic pheochromocytoma/secreting paraganglioma	Enrichment	RET	2.31
82	Inherited cancer-predisposing syndrome	Enrichment	EGFR, RET	2.31
83	Squamous cell carcinoma, head and neck	Enrichment	EGFR	2.25
84	Brugada syndrome 1	Enrichment	KCNH2	2.25
85	Developmental dysplasia of the hip 1	Enrichment	AKR1C1	2.24
86	Digeorge syndrome	Enrichment	COMT	2.21
87	Alzheimer disease, familial, 1	Enrichment	MPO	2.20
88	Renal hypodysplasia/aplasia 1	Enrichment	RET	2.19
89	Hypothyroidism	Enrichment	RET	2.19
90	Myelofibrosis	Enrichment	JAK2	2.17
91	Essential thrombocythemia	Enrichment	JAK2	2.17
92	Congenital central hypoventilation syndrome	Enrichment	RET	2.14
93	Renal agenesis, bilateral	Enrichment	RET	2.14
94	Pseudoxanthoma elasticum	Enrichment	ABCC2	2.13
95	Familial hypercholanemia	Enrichment	EPHX1	2.13
96	Hypertension, essential	Enrichment	CYP3A5	2.13
97	Leukemia, acute lymphoblastic 3	Enrichment	JAK2	2.07
98	Lung non-small cell carcinoma	Enrichment	EGFR	2.05
99	Renal hypodysplasia/aplasia 3	Enrichment	RET	2.01
100	Lip and oral cavity carcinoma	Enrichment	EGFR	2.01
101	Congenital long qt syndrome	Enrichment	KCNH2	2.01
102	Pheochromocytoma	Enrichment	RET	1.95
103	Lung cancer susceptibility 3	Enrichment	EGFR	1.95
104	Epicanthus	Enrichment	ACVR1	1.94
105	Gliosarcoma	Enrichment	EGFR	1.89
106	Giant cell glioblastoma	Enrichment	EGFR	1.86
107	Arteriovenous malformations of the brain	Enrichment	EGFR	1.82
108	Hereditary paraganglioma-pheochromocytoma syndromes	Enrichment	RET	1.77
109	Hepatocellular carcinoma	Enrichment	RET	1.75
110	Lung cancer	Enrichment	CYP2A6	1.73
111	Brugada syndrome	Enrichment	KCNH2	1.68
112	Bardet-biedl syndrome	Enrichment	COMT	1.67
113	Bladder cancer	Enrichment	EGFR	1.63
114	Hirschsprung disease 1	Enrichment	RET	1.63
115	Differentiated thyroid carcinoma	Enrichment	RET	1.63
116	Long qt syndrome 1	Enrichment	KCNH2	1.62
117	Long qt syndrome	Enrichment	KCNH2	1.60
118	Familial hypertrophic cardiomyopathy	Enrichment	KCNH2	1.58
119	Schizophrenia	Enrichment	COMT	1.52
120	Hereditary breast carcinoma	Enrichment	RET	1.45
121	Leukemia, acute myeloid	Enrichment	JAK2	1.42
122	Sensorineural hearing loss	Enrichment	RET	1.42
123	Primary ovarian insufficiency	Enrichment	CYP19A1	1.41
124	Cystic fibrosis	Enrichment	EPHX1	1.40
125	Body mass index quantitative trait locus 11	Enrichment	KCNH2	1.40
126	Hypertelorism	Enrichment	RET	1.38
127	Breast cancer	Enrichment	RET	1.23
128	Colorectal cancer	Enrichment	RET	1.17
129	Rare autosomal dominant non-syndromic sensorineural deafness type dfna	Enrichment	ABCC1	1.15

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Clomipramine Pathway, Pharmacokinetics

Pathway Network for Clomipramine Pathway, Pharmacokinetics

Pathway network for the Clomipramine Pathway, Pharmacokinetics SuperPath

Member Pathways for Clomipramine Pathway, Pharmacokinetics

Pathways in the Clomipramine Pathway, Pharmacokinetics SuperPath

Associated Genes for Clomipramine Pathway, Pharmacokinetics

Associated Disorders for Clomipramine Pathway, Pharmacokinetics

Disorders associated with Clomipramine Pathway, Pharmacokinetics SuperPath

STRING Interaction Network for Clomipramine Pathway, Pharmacokinetics

Sources for Clomipramine Pathway, Pharmacokinetics